P-glycoprotein mediated multidrug resistance and its implications for pathology

References

• De Graaf, D, Sharma, RC, Mechetner, EB, et al. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carriermediated methotrexate uptake. Proc Natl Acad Sci USA 1996; 93: 1238–1242
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385–427
   PubMed Web of Science ®Google Scholar
• Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 221: 1285–1288
   PubMed Web of Science ®Google Scholar
• Roninson, IB, Abelson, HT, Housman, DE, et al. Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells. Nature 1984; 309: 626–628
   PubMed Web of Science ®Google Scholar
• Kartner, N, Evernden-Porelle, D, Bradley, G, et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820–823
   PubMed Web of Science ®Google Scholar
• Riordan, JR, Deuchars, K, Kartner, N, et al. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985; 316: 817–819
   PubMed Web of Science ®Google Scholar
• Ueda, K, Cornwell, MM, Gottesman, MM, et al. The mdrl gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986; 141: 956–962
   PubMed Web of Science ®Google Scholar
• Gros, P, Ben Neriah, YB, Croop, JM, et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323: 728–731
   PubMed Web of Science ®Google Scholar
• Pastan, I, Gottesman, MM, Ueda, K, et al. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988; 85: 4486–4490
   PubMed Web of Science ®Google Scholar
• Shapiro AB, Ling V. Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 1995; 270: 16167–16175
   PubMed Web of Science ®Google Scholar
• Beck WT, Qian XD. Photoaffinity substrates for P-glycoprotein. Biochem Pharmacol 1992; 43: 89–93
   PubMed Web of Science ®Google Scholar
• Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 1988; 85: 3580–3584
   PubMed Web of Science ®Google Scholar
• Konen, PL, Currier, SJ, Rutherford, AV, et al. The multidrug transporter: rapid modulation of efflux activity monitored in single cells by the morphologic effects of vinblastine and daunomycin. J Histochem Cytochem 1989; 37: 1141–1145
   PubMed Web of Science ®Google Scholar
• Hammond JR, Johnstone RM, Gros P. Enhanced efflux of [3H]vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the mdr1 gene. Cancer Res 1989; 49: 3867–3871
   PubMed Web of Science ®Google Scholar
• Ambudkar, SV, Lelong, IH, Zhang, J, et al. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA 1992; 89: 8472–8476
   PubMed Web of Science ®Google Scholar
• Sharom FJ, Yu X, Doige CA. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 1993; 268: 24197–24202
   PubMed Web of Science ®Google Scholar
• Schurr, E, Raymond, M, Bell, JC, et al. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res 1989; 49: 2729–2733
   PubMed Web of Science ®Google Scholar
• Azzaria M, Schurr E, Gros P. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol Cell Biol 1989; 9: 5289–5297
   PubMed Web of Science ®Google Scholar
• Chen, CJ, Chin, JE, Ueda, K, et al. Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381–389
   PubMed Web of Science ®Google Scholar
• Chen, CJ, Clark, D, Ueda, K, et al. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990; 265: 506–514
   PubMed Web of Science ®Google Scholar
• Childs S, Ling V. The MDR superfamily of genes and its biological implications. Important advances in oncolocy 1994, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott Company, Philadelphia 1994; 21–36, In
   Google Scholar
• Ames GF. The basis of multidrug resistance in mammalian cells: homology with bacterial transport. Cell 1986; 47: 323–324
   PubMed Web of Science ®Google Scholar
• Cornwell, MM, Safa, AR, Felsted, RL, et al. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci USA 1986; 83: 3847–3850
   PubMed Web of Science ®Google Scholar
• Ferry DR, Russell MA, Cullen MH. P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site. Biochem Biophys Res Commun 1992; 188: 440–445
   PubMed Web of Science ®Google Scholar
• Pawagi, AB, Wang, J, Silverman, M, et al. Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional rolc in broad substrate specificity. J Mol Biol 1994; 235: 554–564
   PubMed Web of Science ®Google Scholar
• Higgins CF, Gottesman MM. Is the multidrug transporter a flippase?. Trends Biochem Sci 1992; 17: 18–21
   PubMed Web of Science ®Google Scholar
• Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53: 747–754
   PubMed Web of Science ®Google Scholar
• Homolya, L, Hollo, Z, German, UA, et al. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993; 268: 21493–21496
   PubMed Web of Science ®Google Scholar
• Shapiro AB, Ling V. Using purified P-glycoprotein to understand multidrug resistance. J Bioenerg Biomembr 1995; 27: 7–13
   PubMed Web of Science ®Google Scholar
• Fojo, AT, Ueda, K, Slamon, DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265–269
   PubMed Web of Science ®Google Scholar
• Goldstein, LJ, Glaski, H, Fojo, A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116–124
   PubMed Web of Science ®Google Scholar
• Kakehi, Y, Kanamaru, H, Yoshida, O, et al. Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 1988; 139: 862–865
   PubMed Web of Science ®Google Scholar
• Tsuruo, T, Sugimoto, Y, Hamada, H, et al. Detection of multidrug resistance markers, P-glycoprotein and mdr1 mRNA, in human leukemia cells. Jpn J Cancer Res 1987; 78: 1415–1419
   PubMedGoogle Scholar
• Holmes, J, Jacobs, A, Carter, G, et al. Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 1989; 72: 40–44
   PubMed Web of Science ®Google Scholar
• Ludescher, C, Hilbe, W, Eisterer, W, et al. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 1993; 85: 1751–1758
   PubMed Web of Science ®Google Scholar
• Ma, DD, Scurr, RD, Davey, RA, et al. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet 1987; 1: 135–137
   PubMed Web of Science ®Google Scholar
• Schneider, J, Bak, M, Efferth, T, et al. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989; 60: 815–818
   PubMed Web of Science ®Google Scholar
• Ma DD, Bell DR. Multidrug resistance and P-glycoprotein expression in human cancer. Aust NZ J Med 1989; 19: 736–743
   PubMedGoogle Scholar
• Grogan, TM, Spier, CM, Salmon, SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490–495
   PubMed Web of Science ®Google Scholar
• Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994; 13: 223–233
   PubMed Web of Science ®Google Scholar
• Kohno, K, Sato, S, Takano, H, et al. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 1989; 165: 1415–1421
   PubMed Web of Science ®Google Scholar
• Lepelley, P, Soenen, V, Preudhomme, C, et al. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 1994; 8: 998–1004
   PubMed Web of Science ®Google Scholar
• Goasguen, JE, Dossot, JM, Fardel, O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemai: prognostic implications. Blood 1993; 81: 2394–2398
   PubMed Web of Science ®Google Scholar
• Kuwazuru, Y, Yoshimura, A, Hanada, S, et al. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868–873
   PubMed Web of Science ®Google Scholar
• Kuttesch, JF, Parham, DM, Luo, X, et al. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 1996; 14: 886–900
   PubMed Web of Science ®Google Scholar
• Chan, HS, Thorner, PS, Haddad, G, et al. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689–704
   PubMed Web of Science ®Google Scholar
• Norris, MD, Bordow, SB, Marshall, GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 231–238
   PubMed Web of Science ®Google Scholar
• Benard, J, Bourhis, J, de Vathaire, F, et al. Prognostic value of MDRl gene expression in neuroblastoma: results of a multivariate analysis. Prog Clin Biol Res 1994; 385: 111–116
   PubMedGoogle Scholar
• Chan, HS, Haddad, G, Thorner, PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325: 1608–1614
   PubMed Web of Science ®Google Scholar
• Pu, YS, Tsai, TC, Cheng, AL, et al. Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response. J Urol 1996; 156: 271–275
   PubMed Web of Science ®Google Scholar
• Shinohara, N, Nonomura, K, Takakura, E, et al. Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell carcinomas of the upper urinary tract. Eur Urol 1994; 26: 327–333
   PubMed Web of Science ®Google Scholar
• Del Poeta, G, Stasi, R, Aronica, G, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87: 1997–2004
   PubMed Web of Science ®Google Scholar
• Lin, SF, Huang, SM, Chen, TP, et al. MDR1 gene expression in acute myeloid leukemia: clinical correlation. J Formos Med Assoc 1995; 94: 111–116
   PubMedGoogle Scholar
• Wood, P, Burgess, R, MacGregor, A, et al. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994; 87: 509–514
   PubMed Web of Science ®Google Scholar
• Zochbauer, S, Gsur, A, Brunner, R, et al. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994; 8: 974–977
   PubMed Web of Science ®Google Scholar
• Schneider J, Romero H. Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffinembedded tumor samples from breast cancer patients. Anticancer Res 1995; 15: 1117–1121
   PubMed Web of Science ®Google Scholar
• He, L, Hao, C, Lin, B, et al. P-glycoprotein expression in primary breast cancer. Chin Med Sci J 1995; 10: 12–15
   PubMedGoogle Scholar
• Verrelle, P, Meissonnier, F, Fonck, Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma [see comments]. J Natl Cancer Inst 1991; 83: 111–116
   PubMed Web of Science ®Google Scholar
• Ro, J, Sahin, A, Ro, JW, et al. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer [see comments]. Hum Pathol 1990; 21: 787–791
   PubMed Web of Science ®Google Scholar
• Veneroni, S, Zaffaroni, N, Daidone, MG, et al. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorbuicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994; 30A: 1002–1007
   PubMed Web of Science ®Google Scholar
• Grant, CE, Valdimarsson, G, Hipfner, DR, et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357–361
   PubMed Web of Science ®Google Scholar
• Cole, SP, Bhardwaj, G, Gerlach, JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [see comments]. Science 1992; 258: 1650–1654
   PubMed Web of Science ®Google Scholar
• Ota, E, Abe, Y, Oshika, Y, et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 1995; 72: 550–554
   PubMed Web of Science ®Google Scholar
• List, AF, Spier, CS, Grogan, TM, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464–2469
   PubMed Web of Science ®Google Scholar
• Izquierdo, MA, van der Zee, AG, Vermorken, JB, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230–1237
   PubMed Web of Science ®Google Scholar
• Beck WT. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst 1989; 81: 1683–1685
   PubMed Web of Science ®Google Scholar
• Sauerbrey A, Zintl F, Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer 1994; 70: 1144–1149
   PubMed Web of Science ®Google Scholar
• Tiirikainen, MI, Elonen, E, Syrjala, MT, et al. Flow cytometric analysis of glutathione-S-transferase-pi in acute leukemia. Leukemia 1994; 8: 978–984
   PubMed Web of Science ®Google Scholar
• Su, GMI, Davey, MW, Davey, RA, et al. Development of extended multidrug resistance in HL60 promyelocytic leukaemia cells. Br J Haematol 1994; 88: 566–574
   PubMed Web of Science ®Google Scholar
• Izquierdo, MA, Shoemaker, RH, Flens, MJ, et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996; 65: 230–237
   PubMed Web of Science ®Google Scholar
• Gekeler, V, Beck, J, Noller, A, et al. Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann Hematol 1994; 69(Suppl 1)S19–S24
   PubMed Web of Science ®Google Scholar
• Chan, HS, DeBoer, G, Thorner, PS, et al. Multidrug resistance. Clinical opportunities in diagnosis and circumvention. Hematol Oncol Clin North Am 1994; 8: 383–410
   PubMed Web of Science ®Google Scholar
• Trambas CM, Woods GM. Assessment of the available techniques for analysis of P-glycoprotein mediated multidrug resistance. Australian Journal of Medical Science 1995; 16: 143–146
   Google Scholar
• Beck, WT, Grogan, TM, Willman, CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 3010–3020
   PubMed Web of Science ®Google Scholar
• Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990; 10: 1652–1663
   PubMed Web of Science ®Google Scholar
• Schinkel, AH, Mol, CA, Wagenaar, E, et al. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995; 31A: 1295–1298
   PubMed Web of Science ®Google Scholar
• Thiebaut, F, Tsuruo, T, Hamada, H, et al. Cellular localization of the multidrug-resistance gene product P- glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735–7738
   PubMed Web of Science ®Google Scholar
• Kamimoto, Y, Gatmaitan, Z, Hsu, J, et al. The function of Gpl70, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 1989; 264: 11693–11698
   PubMed Web of Science ®Google Scholar
• Klohs WD, Steinkampf RW. Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells. Cancer Res 1988; 48: 3025–3030
   PubMed Web of Science ®Google Scholar
• Phang, JM, Poore, CM, Lopaczynska, J, et al. Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells. Cancer Res 1993; 53: 5977–5981
   PubMed Web of Science ®Google Scholar
• Penny JI, Campbell FC. Active transport of benzo[a]pyrene in apical membrane vesicles from normal human intestinal epithelium. Biochim Biophys Acta 1994; 1226: 232–236
   PubMed Web of Science ®Google Scholar
• Lanning, CL, Fine, RL, Sachs, CW, et al. Chlorpyrifos oxon interacts with the mammalian multidrug resistance protein, P-glycoprotein. J Toxicol Environ Health 1996; 47: 395–407
   PubMed Web of Science ®Google Scholar
• Arceci, RJ, Croop, JM, Horwitz, SB, et al. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988; 85: 4350–4354
   PubMed Web of Science ®Google Scholar
• Sugawara, I, Nakahama, M, Hamada, H, et al. Apparent stronger expression in the human adrenal cortex than in the human adrenal medulla of Mr 170,000–180,000 P-glycoprotein. Cancer Res 1988; 48: 4611–4614
   PubMed Web of Science ®Google Scholar
• Naito M, Yusa K, Tsuruo T. Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein. Biochem Biophys Res Commun 1989; 158: 1066–1071
   PubMed Web of Science ®Google Scholar
• Yang, CP, DePinbo, SG, Greenberger, LM, et al. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 1989; 264: 782–788
   PubMed Web of Science ®Google Scholar
• Qian XD, Beck WT. Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts. J Biol Chem 1990; 265: 18753–18756
   PubMed Web of Science ®Google Scholar
• Ueda, K, Okamura, N, Hirai, M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267: 24248–24252
   PubMed Web of Science ®Google Scholar
• Wolf DC, Horwitz SB. P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. Int J Cancer 1992; 52: 141–146
   PubMed Web of Science ®Google Scholar
• van Kalken, CK, Broxterman, HJ, Pinedo, HM, et al. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 1993; 67: 284–289
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo, C, O'Brien, JP, Casals, D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–698
   PubMed Web of Science ®Google Scholar
• Schinkel, AH, Smit, JJ, van Tellingen, O, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491–502
   PubMed Web of Science ®Google Scholar
• Drach, D, Zhao, S, Drach, J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729–2734
   PubMed Web of Science ®Google Scholar
• Drach, J, Gsur, A, Hamilton, G, et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996; 88: 1747–1754
   PubMed Web of Science ®Google Scholar
• Raghu, G, Park, SW, Roninson, IB, et al. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 1996; 24: 1258–1264
   PubMed Web of Science ®Google Scholar
• Gupta, S, Kim, CH, Tsuruo, T, et al. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol 1992; 12: 451–458
   PubMed Web of Science ®Google Scholar
• Chong, AS, Markham, PN, Gebel, HM, et al. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 1993; 36: 133–139
   PubMed Web of Science ®Google Scholar
• Markham, PN, Coon, JS, Chong, AS, et al. Natural killer cell cytotoxicity and the multidrug resistance gene. Transplant Proc 1993; 25: 96–97
   PubMed Web of Science ®Google Scholar
• Robert J. Proposals for concomitant use of several modulators of multidrug resistance in clinics. Anticancer Res 1994; 14: 2371–2373
   PubMed Web of Science ®Google Scholar
• Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993; 72: 3553–3563
   PubMed Web of Science ®Google Scholar
• Mickisch, GH, Pai, LH, Siegsmund, M, et al. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice. J Urol 1993; 149: 174–178
   PubMed Web of Science ®Google Scholar
• FitzGerald, DJ, Willingham, MC, Cardarelli, CO, et al. A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 1987; 84: 4288–4292
   PubMed Web of Science ®Google Scholar
• Mickisch, GH, Pai, LH, Gottesman, MM, et al. Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug resistant transgenic mice. Cancer Res 1992; 52: 4427–4432
   PubMed Web of Science ®Google Scholar
• Allavena, P, Grandi, M, D'Incalci, M, et al. Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes. Int J Cancer 1987; 40: 104–107
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini, C, Rivoltini, L, Supino, R, et al. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. Cancer Res 1988; 48: 2372–2376
   PubMed Web of Science ®Google Scholar
• Rivoltini, L, Colombo, MP, Supino, R, et al. Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 1990; 46: 727–732
   PubMed Web of Science ®Google Scholar
• Mooney, EF, Dye, JF, Guilluo, PJ, et al. Multidrug-resistant colonic cancer cell line LoVoDx is efficiently killed by lymphokine-activated killer cells from patients with carcinoma of the colon. Br J Surg 1993; 80: 1259–1261
   PubMed Web of Science ®Google Scholar
• Sorrentino, BP, Brandt, SJ, Bodine, D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103
   PubMed Web of Science ®Google Scholar
• Mickisch, GH, Aksentijevich, I, Schoenlein, PV, et al. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992; 79: 1087–1093
   PubMed Web of Science ®Google Scholar
• Koc, ON, Allay, JA, Lee, K, et al. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 1996; 23: 46–65
   PubMed Web of Science ®Google Scholar
• Lum, BL, Fisher, GA, Brophy, NA, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 1993; 72: 3502–3514
   PubMed Web of Science ®Google Scholar
• Horio, M, Lovelace, E, Pastan, I, et al. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles. Biochim Biophys Acta 1991; 1061: 106–110
   PubMed Web of Science ®Google Scholar
• Chambers TC, Zheng B, Kuo JF. Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol 1992; 41: 1008–1015
   PubMed Web of Science ®Google Scholar
• Erlichman, C, Moore, M, Thiessen, JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993; 53: 4837–4842
   PubMed Web of Science ®Google Scholar
• Lum, BL, Kaubisch, S, Yahanda, AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635–1642
   PubMed Web of Science ®Google Scholar
• Callaghan R, Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem 1993; 268: 16059–16064
   PubMed Web of Science ®Google Scholar
• Jette, L, Murphy, GF, Leclerc, JM, et al. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 1995; 50: 1701–1709
   PubMed Web of Science ®Google Scholar